Biologic therapy in Crohn's disease: Review of the evidence

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

It is expected that within a few months, there will be commercially available in the United States a total of 3 biologic agents with inhibition of tumor necrosis factor-α. (TNF-α) as the primary mechanism of action: infliximab, adalimumab, and certolizumab pegol. The primary efficacy data for each of these agents are reviewed. All 3 agents appear to be efficacious for both induction and maintenance of remission in Crohn's disease. There are no trials comparing these agents, but one can infer from available data that they have broadly similar efficacy. Adverse events associated with anti-TNF-α therapy, including infection, infusion reactions, autoimmunity, risk of malignancy, and neurologic events, are reviewed.

Original languageEnglish (US)
Pages (from-to)S3-S12
JournalReviews in gastroenterological disorders
Volume7
Issue numberSUPPL. 1
StatePublished - Mar 9 2007

Keywords

  • Adalimumab
  • Certolizumab pegol
  • Crohn's disease
  • Infliximab
  • TNF-α

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Biologic therapy in Crohn's disease: Review of the evidence'. Together they form a unique fingerprint.

Cite this